Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05431543 | Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia | PHASE2 | COMPLETED | 59 | — | — | Aug 6, 2022 | Dec 14, 2022 | Sep 5, 2024 | 5 | United States |
| NCT05294328 | Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia | PHASE2 | COMPLETED | 68 | — | — | May 5, 2022 | Sep 10, 2022 | Sep 5, 2024 | 5 | United States |
Percentage of participants with at least a 3-line improvement in near vision and no loss ≥ 5 letters distance vision
| Arm | Type | Description |
|---|---|---|
| Combination ophthalmic solution (LNZ101) dosed bilaterally | EXPERIMENTAL | LNZ 101: Aceclidine/Brimonidine combination ophthalmic solution |
| Aceclidine Ophthalmic Solution (LNZ100) dosed bilaterally | EXPERIMENTAL | LNZ 100: Aceclidine ophthalmic solution |
| Vehicle Ophthalmic Solution dosed bilaterally | EXPERIMENTAL | Proprietary vehicle ophthalmic solution |
| Name | Type | Description |
|---|---|---|
| Aceclidine+Brimonidine combination ophthalmic solution | DRUG | LNZ101-combination ophthalmic solution |
| Aceclidine ophthalmic solution | DRUG | LNZ100- aceclidine ophthalmic solution |
| Vehicle proprietary ophthalmic solution | DRUG | Proprietary Vehicle ophthalmic solution |
Inclusion Criteria: 1. Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed; 2. Be able and willing to follow all instructions and attend study visits; 3. Be 45-75 years of ag...